Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD;Intravitreale anti-VEGF-therapie mit bevacizumab bei neovaskulärer AMD

Ophthalmologe

Volumn 105, Issue 6, 2008, Pages 538-543

  Schaal, K B ^a   Engler, C ^a   Schutt F ^a   Scheuerle, A ^a   Dithmar, S ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Age related macular degeneration (AMD); Anti VEGF therapy; Bevacizumab; Choroidal neovascularization (CNV); Vascular endothelial growth factor (VEGF)

Indexed keywords

EID: 46449112783     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-007-1638-2     Document Type: Article

References (17)

1. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372
2. Axer-Siegel R, Ehrlich R, Rosenblatt I et al. (2004) Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 122: 453-459
3. Bashshur ZF, Bazarbachi A, Schakal A et al. (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142: 1-9
4. Bird AC, Marshall J (1986) Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc U K 105: 674-682
5. Cohen SY, Creuzot-Garcher C, Darmon J et al. (in press) Types of Choroidal Neovascularization (CNV) in Newly Diagnosed Exudative Age-related Macular Degeneration (AMD). Br J Ophthalmol: Epub ahead of print
6. Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: Using the internet to assess drug sagety woldwide. Br J Ophthalmol 90: 1344-1349
7. Gross-Jendroska M, Flaxel CJ, Schwartz SD et al. (1998) Treatment of pigment epithelial detachments due to age-related macular degeneration with intra-ocular C3F8 injection. Aust N J Ophthalmol 26: 311-317
8. Ladewig MS, Ziemssen F, Jaissle G et al. (2006) Intravitreales Bevacizumab bei der neovaskulären altersabhängigen Makuladegeneration. Ophthalmologe 103: 463-470
9. Leung CK, Chan WM, Chong KK et al. (2007) Alignment artifacts in optical coherence tomography analyzed images. Ophthalmology 114: 263-270
10. Meyer CH, Mennel S, Schmidt JC, Kroll P (2006) Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 90: 1207-1208
11. Nicolo M, Ghiglione D, Lai S, Calabria G (2005) Intravitreal triamcinolone in the treatment of serous pigment epihtelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 15: 415-419
12. Pauleikhoff D, Löffert D, Spital G et al. (2002) Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 40: 533-538
13. Pauleikhoff D, Bornfeld N, Gabel VP et al. (2005) Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte. Klin Monatsbl Augenheilkd 222: 381-388
14. Rich RM, Rosenfeld PJ, Puliafito CA et al. (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495-511
15. Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431
16. Singh RP, Sears JE (2006) Retinal pigment epithelial tears after pegaptanib injection for exudative age-ralated macular degeneration. Am J Ophthalmol 142: 160-162
17. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Groups (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No.1. Am J Ophthalmol 136: 407-418